Thetis Pharmaceuticals Announces Patent Issuance in Korea for First-in-Class Resolvin E1 Drug (8/24/2022)
Patent expands coverage to the 3rd largest market in Asia
Essex, CT – (August 24, 2022) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a small molecule ChemR23 agonist to treat cancer and chronic inflammatory diseases, announced that the Korea Intellectual Property Office has granted patent KR 10-2437682 providing composition of matter protection for TP-317.
“TP-317 is a novel small molecule that represents a highly differentiated approach to regulating immune homeostasis with broad therapeutic potential in cancer and chronic inflammatory diseases,” said Gary Mathias, co-founder and CEO of Thetis. “With long-term patents issued in the U.S., Europe, Japan, China and now Korea, TP-317 has the intellectual property foundation to support clinical development throughout Asia.”
About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and chronic inflammatory diseases. Thetis’ proprietary HEALER™ technology enables the pharmaceutical development of Resolvins, overcoming the stability, manufacturing, and formulation hurdles that have limited their commercial development. Thetis is supported by venture capital investors, NIH, and leading private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.
Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.
Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com